Kane Biotech Inc. KNE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 17.40% | -134.86% | -143.75% | -157.43% | -167.70% |
| Total Depreciation and Amortization | -50.21% | -36.42% | -26.95% | -11.61% | -12.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -63.76% | 99.36% | 100.68% | 105.12% | 107.39% |
| Change in Net Operating Assets | 65.08% | 57.50% | 12.39% | 49.91% | 51.74% |
| Cash from Operations | 10.61% | 37.42% | 22.82% | 35.13% | 41.03% |
| Capital Expenditure | 100.00% | 126.67% | 82.42% | 67.51% | 44.20% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -93.93% | -99.39% |
| Other Investing Activities | 31.91% | 84.38% | -115.51% | -129.64% | -107.01% |
| Cash from Investing | 79.91% | -100.23% | -100.49% | -99.98% | -100.55% |
| Total Debt Issued | -102.75% | -- | -- | -- | 0.00% |
| Total Debt Repaid | 92.22% | 97.61% | 95.39% | 93.33% | 91.34% |
| Issuance of Common Stock | -42.48% | -14.22% | 421.19% | 1,069.16% | 660.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 112.23% | 97.93% | 97.52% | 93.89% | 93.60% |
| Cash from Financing | -49.39% | 141.65% | 148.83% | 143.17% | 152.67% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -228.94% | 91.40% | 134.60% | 135.57% | 559.91% |